The University of Virginia is participating a clinical research study for adults ages 18 and over, who have folate receptor alphas (FRa)–positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers. The purpose of this study is to look at the efficacy and safety of using the investigational study drug, mirvetuximab soravtansine (MIRV) in combination with bevacizumab (BEV) as maintenance therapy, compared to bevacizumab alone.

The UVA Center for Diabetes Technology seeks adults 18 years or older who have Type 1 Diabetes and is currently using a Tandem Control-IQ (CIQ) insulin pump to participate in a research study.

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who had high-risk melanoma skin cancer, but are now melanoma free following surgery. The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab in participants that have had melanoma removal surgery but are still at high risk for the recurrence of the disease.

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with HPV 16+ confirmed head and neck squamous cell carcinoma(HNSCC) for the H-200-001 research study.
The Phase 2 H-200-001 Study is looking at 2 investigational study drugs, called HB-201 and HB-202, to see how well they work and how safe they are when given with pembrolizumab to patients with HPV 16+ HNSCC. These drugs are believed to stimulate the immune cells to help attack and kill HPV 16 cancer cells.

The department of Kinesiology seeks adults ages 50 and older with peripheral artery disease (PAD) for a research study. The purpose of the study is to determine the effects of beetroot juice on walking ability in people with blockages in their leg arteries. Beetroot juice is made from beets and early evidence suggests drinking beetroot juice may improve blood flow to the legs and leg muscle function.

The UVA Center for Leading Edge Addiction Research or CLEAR clinic is seeking men and women ages 18 to 55 who want to reduce their cannabis usage to participate in a research study to test the effectiveness of an investigational medication. The purpose of the study is to see if the investigational drug is effective in reducing withdrawal symptoms in individuals who want to eliminate their regular cannabis usage.

The University of Virginia Center for Diabetes Technology is seeking adults 18-40 years old diagnosed with type 1 diabetes for a research study. The purpose of this study is to examine the cardiovascular effects while using the artificial pancreas (AP) technology.

The department of Kinesiology seeks adults ages 65 and older with Heart Failure with reduced ejection fraction (HFrEF) for a research study. The purpose of the study is to determine whether performing a hybrid Cardio-resistance training program (PRIME) results in better health outcomes than the traditional exercise training program used with individuals with heart failure. Exercise training is a proven therapy for prolonging both lifespan and health-span in individuals with HFrEF.

The Department of Radiology and Medical Imaging seeks active-duty service members and veterans aged 18-65 with a history of blast exposure for a research study. The purpose of the study is to better understand brain injury in people who have been exposed to blast events.

You may be eligible for this study if: you are an active-duty service member or veteran, have a history of blast exposure and are willing to travel to Charlottesville, VA.

The University of Virginia Comprehensive Cancer Center) seeks adults ages 18 and over with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) for a research study. The purpose of the study is to compare the usual treatment for NSCLC to a study treatment that combines the drugs ramucirumab and pembrolizumab. The combination of ramucirumab and pembrolizumab is not approved by the FDA to treat advanced lung cancer. Participants in this study will be randomly selected to continue with the usual treatment for NSCLC or receive the investigational drugs.